30 results about "Cellular secretion" patented technology

A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.

This invention relates to a pharmaceutical composition for treating autoimmune diseases. The pharmaceutical composition for treating autoimmune diseases comprises an antibody and an inhibitor, wherein the antibody includes at least one of an OX40 antibody and an OX40L antibody, and the inhibitor includes at least one of a Janus kinase inhibitor and a RORγt inhibitor. In the above-mentioned pharmaceutical composition for treating autoimmune diseases, the Janus kinase inhibitor and / or the RORγt inhibitor can inhibit the secretion of IL17A by Treg cells induced by OX40 antibody and / or OX40L antibody, thereby reducing IL17A-promoted pathological inflammation and improving the efficacy of OX40 antibody and / or OX40L antibody in treating autoimmune diseases.

A reagent, a drug source material, a drug, a quasi-drug, a cosmetic source material, or a cosmetic that includes a supernatant of a culture solution of stem cells and is for reducing skin redness or inflammation, inflammation, number of pores, pore size, skin spots, and sebum. A reagent, a drug source material, a drug, a quasi-drug, a cosmetic source material, or a cosmetic that includes a secretion of stem cells and is for reducing skin redness or inflammation, inflammation, number of pores, pore size, skin spots, and sebum. The secretion of the stem cells may be extracellular vesicles. The secretion of the stem cells may be exosomes.

The present application provides a kind of oil composition, containing monounsaturated fatty acid, polyunsaturated fatty acid, monounsaturated fatty acid is omega-9 fatty acid;Polyunsaturated acid is the mixture of omega-6 fatty acid and omega-3 fatty acid.The present application can repair and resist aging, all-purpose skin care, increase epidermal thickness, enhance barrier, anti-inflammatory soothing, anti-wrinkle firming, soothing repair red, nourish skin, and can be applied to sensitive skin, can inhibit LPS-induced HaCaT cell IL-6 secretion, increase the thickness of 3D skin model epidermis layer, and can promote the expression of silk aggregate protein (FLG), ceramide synthase 3 (CerS3), desmoglein core glycoprotein (DSG1) which has important role for skin barrier function, indicating that it can alleviate the inflammatory response produced by LPS stimulation HaCaT cell and has enhanced skin barrier function.

This invention discloses a preparation process for a homogeneous immunomodulatory polysaccharide from *Gynostemma pentaphyllum* and its application in the preparation of anti-melanoma drugs and immunomodulators, relating to the field of pharmaceutical manufacturing technology. The preparation process includes four steps: compound enzyme-ultrasound synergistic extraction, fractional alcohol precipitation to remove proteins, DEAE-52 ion exchange column chromatography, and Sephacryl S-400 gel permeation chromatography purification. The resulting homogeneous polysaccharide (GOP-3) has a weight-average molecular weight of 12±1 kDa and is composed of mannose, glucose, and galactose in a specific ratio. The GOP-3 of this invention has a weight-average molecular weight (Mw) of 12.8 kDa, a dispersion (Mw / Mn) < 1.2, a uronic acid content of 23.5%, a well-defined structure, and is suitable for drug application. Furthermore, GOP-3 can significantly promote the secretion of IL-12 by dendritic cells and induce the differentiation of naive T cells into Th1 cells. Simultaneously, compared with a full-dose PD-1 monoclonal antibody, the combination of GOP-3 and a half-dose monoclonal antibody not only reduces the risk of immune-mediated pneumonia caused by antibody drugs but also increases the tumor inhibition rate by more than 40%.

The application discloses application of ostruthin in enhancing CAR-T cell anti-tumor function, belongs to the technical field of biological medicine, and the ostruthin can promote cell proliferation, inhibit cell exhaustion, promote the secretion of cytokines related to killing cancer cells, and further enhance the anti-tumor function of CAR-T cells in vivo and in vitro as a cell enhancer of CAR-T cells; experimental results show that when ostruthin is combined with CAR-T cells for anti-tumor treatment, compared with ostruthin or CAR-T cells alone, the combination of the two can significantly inhibit the growth of solid tumors. The application provides a new technical means for improving the tumor treatment effect of CAR-T cell immunotherapy.

The application discloses a preparation method of a concentrated growth factor bone repair material for inducing macrophages to produce pro-osteogenic secretions and application thereof, and steps of the preparation method comprise the following steps: a, standardization preparation of a concentrated growth factor extraction liquid CGFe; b, screening and determination of 2*CGFe as an optimal concentration; c, verification of macrophage secretion induction and mechanism regulation; and d, preparation of a GelMA photocured composite hydrogel loaded with the CGFe. The concentrated growth factor bone repair material prepared by the preparation method is applied to bone defect repair. The prepared CGFe is used as a "biological switch", which can specifically inhibit a NF-kappa B signal path of macrophages and induce the macrophages to transform from a pro-inflammatory state to a repair state with abundant osteogenic factors. The concentrated growth factor bone repair material initiates an immune cell secretion-stem cell osteogenesis cascade regeneration reaction in situ in a body, and endogenous secretions are innovatively used to replace exogenous factors.

This invention discloses an RSV pre-F trimer protein combination and its application in the preparation of a bivalent RSV vaccine, relating to the field of human vaccine technology. The vaccine is prepared by mixing equal masses of RSV-A and RSV-B subtype pre-F trimer proteins and adding 0.35 mg / 0.5 mL of aluminum hydroxide adjuvant. Both F proteins have their p27 fragment and C-terminal esterification region deleted, and F2 / F1 are linked by GSGSGS. Interchain disulfide bonds are introduced at S146C / N460C and A149C / Y458C sites, and intrachain disulfide bonds are introduced at S155C / S290C sites. After secretion and expression by CHO cells, the pre-F trimer spontaneously assembles into a stable pre-F trimer. The vaccine does not require lyophilization and maintains high purity and the integrity of neutralizing epitopes after storage at 37°C for 28 days. It can significantly induce neutralizing antibodies and T-cell immunity and can be used to prevent various RSV-A / B infections.

Extracellular vesicles (EVs) are natural liposome-like vesicles secreted by cells into the extracellular space. Provided herein are techniques to enrich cargo-loaded EVs over non-loaded EVs and contaminants. To achieve EVs were engineered to display their surface an antigenic tag for fast and efficient EV isolation by immunocapture and a fluorescent protein in the internal space of the EV. Cargo was loaded into the lumen of the EVs by fusing the cargo with an antibody or nanobody that has an affinity for the fluorescent protein of the internal space. To prevent potential antigenicity of the EVs, a TEV cleavage site was included allowing the removal of exposed antigenic tag from immunocaptured EVs, while preserving their luminal cargo.

This invention relates to the field of biotechnology and discloses a stem cell co-expressing miR-449a-5p and miR-30c-5p. The stem cell is constructed by cloning a biomimetic polycistronic expression cassette containing miR-449a-5p and miR-30c-5p into a lentiviral vector and infecting the stem cell, enabling stable and synergistic expression of these two miRNAs. The exosomes (miRNAs-Exos) secreted by these cells specifically enrich miR-449a-5p and miR-30c-5p; after local administration, the exosomes are taken up by skin cells, and the two miRNAs synergistically inhibit the expression of the aging-associated secretory phenotype (SASP) core factors CCL2 and PAI-1, downregulate matrix metalloproteinases MMP-1 / MMP-3, reduce collagen degradation, improve the dermal inflammatory microenvironment, and thereby promote collagen synthesis and skin barrier repair.

The application discloses a multifunctional biomaterial for posterior sclera reinforcement, which is prepared by using layer-by-layer self-assembly (LbL) surface functionalization technology to coat silk fibroin (SF) on the surface of small intestinal submucosa (SIS), and preparing a light cross-linked SF (SFMA) microgroove coating with anisotropic characteristics on one side of the SIS for guiding cell arrangement and growth, promoting tissue regeneration and repair; and preparing a light cross-linked SF and sodium hyaluronate (SF-SH) mixed coating on the other side for improving biocompatibility and adhesion, so as to realize preparation of a multifunctional posterior sclera reinforcement biomaterial with controllable mechanical and degradation properties and capable of promoting surrounding tissue regeneration. The posterior sclera reinforcement biomaterial is cross-linked in the LbL mode to avoid toxic substance residues generated by cross-linking of SIS and traditional glutaraldehyde. The light cross-linked SFMA microgroove coating on one side can not only realize directional growth of fibroblasts, but also realize directional arrangement of collagen type I secreted by the cells, and effectively realize tissue integration. Meanwhile, the light cross-linked SF-SH mixed coating on the other side has excellent adhesion, which is helpful for positioning and attaching of the reinforcement material, and is of great significance to improving the effect of a posterior sclera reinforcement (PSR) operation and promoting long-term stable and effective treatment of pathological high myopia by using the biomaterial.

This invention relates to the field of biomedical technology, and more particularly to a tumor vaccine based on bacterial outer membrane vesicles and tumor-associated glycoantigens, its preparation method, and its application. The tumor vaccine provided by this invention induces increased levels of IL-6 and TNF-α secretion in RAW 264.7 and DC 2.4 cells in vitro, promoting phagocytosis and maturation; in vivo, it induces the maturation of T cells and DC cells in the spleen and lymph nodes, significantly inhibiting tumor growth. The tumor vaccine achieves stable antigen loading, induces a strong immune response, significantly inhibits tumor growth, and demonstrates good efficacy and safety in mouse models.

The present invention relates to the field of biomedicine, and specifically relates to drug development targeting SLC45A2 and application in immunotherapy. In the present invention, SLC45A2 on the surface of T cells is used as a target for immunotherapy. By regulating the SLC45A2 gene or an expression product thereof, the acid-base environment balance of the T cells is regulated and controlled, the ability of the T cells to secrete cytotoxic cytokines is regulated, and the exhaustion process of the T cells is controlled, thereby achieving the regulation and control of the immune function of the T cells. Based on this, in the present invention, a borate bioactive material targeting SLC45A2 is further developed. The material can significantly reduce the expression of SLC45A2, enhance the anti-tumor immune effect of the T cells, and exhibit significant anti-tumor effects both in vivo and in vitro.

This invention discloses a mineralized body for bone repair, its preparation method, and its application. The preparation method includes the following steps: S1, osteogenic-associated cells are cultured in vitro and then subjected to osteogenic induction culture to induce the osteogenic-associated cells to secrete migration bodies and deposit calcium salts; S2, the culture system obtained in step S1 is decellularized to obtain mineralized bodies, wherein the mineralized bodies include the migration bodies and calcium salts. This invention, based on mineralized bodies composed of migration bodies and calcium nodules obtained from osteogenic-associated cells through osteogenic induction culture and decellularization, possesses the characteristics of high interface compatibility and stable binding with materials, and its osteogenic-associated activity remains stable after decellularization. It can induce osteogenic differentiation and promote bone regeneration in vivo, while avoiding the risks associated with live cell transplantation. This provides a novel and efficient cell-free strategy for bone defect repair, which is beneficial for clinical promotion and application.

The present invention relates to the use of compositions comprising specific exosomes secreted by umbilical cord blood mononuclear cells (UCBMNCs) in the prevention and treatment of fibrotic disorders such as fibrotic skin and lung injuries. The exosome compositions of the invention present activity in skin fibrosis and in lung diseases. Moreover, these compositions are also effective in reverting or preventing disease-associated parameters, such of lung diseases, proving its action against respiratory disorders with an inflammatory component, particularly when mediated by macrophages and / or T-cells. Therefore, the present invention lays in the technical domain of pharmaceuticals, medicine, cosmetics, dermo-cosmetics, research and development in cellular biology and appliances thereof.

A method to alleviate chronic pain in humans and animals is disclosed. It comprises administering to said subject p62 / SQSTM1 polypeptide, p62 / SQSTM1 encoding nucleic acid, or mesenchymal stem cells expressing a p62-encoding vector or pretreated to increase the level of p62 protein encoded by the cell's chromosome or secretome from such cells.

This invention relates to the field of single-cell functional analysis and microfluidic chip technology, and discloses a kit and method for in-situ sequential quantitative detection of secreted and intracellular proteins in the same single cell. The kit includes: a microcavity array chip; a secreted protein capture antibody barcode chip and an intracellular protein capture antibody barcode chip; a plastic clamp; a bioaffinity modification reagent; secreted protein standards, intracellular protein standards, secreted protein detection antibody stock solution, and intracellular protein detection antibody stock solution; a fluorescent conjugate, antibody buffer, antibody blocking solution, cell lysis buffer, and cell washing buffer. The method of this invention, through a sequential detection process of first capturing and incubating secreted proteins, followed by in-situ lysis to capture intracellular proteins, achieves high-throughput, high-sensitivity, and high-specificity in-situ sequential quantitative detection of secreted and intracellular proteins in the same single cell without cell transfer or loss of spatial location information. It can establish a correlation analysis of "intracellular signaling pathway activation - external functional output" in single cells, providing a powerful tool for disease mechanism research, drug screening, and immunotherapy evaluation.

This invention relates to viral vectors for delivery of iduronate-2-sulfatase (IDS) to a subject. In some aspects the IDS sequence is optimized for expression in human cells. The invention further relates to methods of using the vector to increase secretion of IDS from a cell and for treatment and prevention of mucopolysaccharidosis II.

A bioreactor system is provided, including: a reactor unit for culturing / proliferating cells or secretion of exosomes from cells; a solution supply unit in which a certain amount of a solution to be supplied to the reactor unit is stored; a circulation pump that is mutually connected to the reactor unit and the solution supply unit by means of a tube and circulates the solution stored in the solution supply unit; and a gas supply unit which includes a main body having a gas storage space filled with gas supplied from outside and is installed in the solution supply unit so as to supply the gas stored in the gas storage space to the solution stored in the solution supply unit, wherein the main body may be arranged to be submerged in the solution filled in the solution supply unit so that the gas can move toward the solution and dissolve.

The present invention provides a method for promoting exosome secretion from animal cells, comprising treating the animal cells with rose-derived exosomes. According to the present invention, the secretion of exosomes from animal cells can be promoted by treating the animal cells with rose-derived exosomes.

This invention belongs to the field of immunotherapy and relates to a method for evaluating the immunogenicity of CAR molecules. The method utilizes dendritic cells (DCs) loaded with CAR molecule peptides, which are then induced to mature and co-cultured with T lymphocytes to obtain CAR-specific cytotoxic T cells. By restimulating the peptides, the IFN-γ secreted by the specific cytotoxic T cells is detected to determine the immunogenicity of the CAR molecule. Compared with existing methods, the detection method and platform described in this invention have advantages such as shorter detection time, higher convenience, less experimental cell consumption, and lower detection cost, and can be used for in vitro evaluation of the immunogenicity of CAR molecules.

The application discloses a chimeric antigen receptor targeting CD180 and application thereof. Through flow cytometry, degranulation analysis experiment and detection of T cell secreted cytokines, it is proved that the T cell modified by the chimeric antigen receptor has a strong killing effect on acute myeloid leukemia cells expressing CD180, has no killing effect on cells not expressing CD180, effectively prevents off-target effect, and does not affect the colony formation ability of umbilical cord blood derived CD34 + hematopoietic stem / progenitor cells, and is safe. The chimeric antigen receptor CD180scFv-CD8alpha-4-1BB-CD3zeta of the application can be used for treating CD180 positive blood tumors.

This invention discloses a bispecific neutralizing antibody, BsAb-H7, for combating H7 subtype influenza virus and its applications. The invention uses two monoclonal antibodies targeting different antigenic epitopes of the H7 subtype influenza virus hemagglutinin protein as parent antibodies: antibody 1F6 targeting epitope M173 and antibody 3B10 targeting epitope N168. The invention also provides a method for expressing and purifying the bispecific neutralizing antibody BsAb-H7, which is expressed via secretion in CHO-S cells and purified by affinity chromatography to obtain the target protein. This bispecific neutralizing antibody BsAb-H7 can specifically bind simultaneously to different antigenic epitopes of the H7 subtype influenza virus hemagglutinin protein, inhibiting H7 subtype influenza virus replication through neutralization. This invention provides an effective tool for the prevention and treatment of H7 subtype influenza virus infection and can be widely applied in combination with other drugs and in other research.

This application relates to the field of pet bone repair, specifically to a nutritional supplement for pet bone repair and regeneration and its preparation method. The supplement comprises the following components in parts by weight: 5 parts non-denatured type II collagen, 10-15 parts hyaluronic acid, 20-25 parts chondroitin sulfate, 6-7 parts hydrogen phosphate, 3-4 parts vitamin D3, 15-20 parts glucosamine hydrochloride, 0.5-1 part manganese glycine, 0.5-1 part magnesium aspartate, and 5-6 parts ascorbate. This application utilizes non-denatured type II collagen to activate regulatory T cells, reducing the release of inflammatory factors and thus alleviating joint pain and swelling; simultaneously, Treg cells secrete growth factors to stimulate chondrocyte regeneration and matrix synthesis, repairing damaged cartilage structure; the other components, combined with non-denatured type II collagen, stimulate chondrocytes to synthesize proteoglycans and collagen fibers, enhancing joint lubrication and cushioning function.

A biologic composition responsive to inflammation has an allograft scaffold matrix for injection or implantation. The allograft scaffold matrix has donor quiescent and / or senescent cells. The donor quiescent and / or senescent cells react in response to signaling of inflammation from host cells or matrix. The reaction to signaling causes the donor quiescent and / or senescent cells to secrete anti-inflammatory cytokines and secrete exosomes to initiate regeneration of the area of the inflammation. The biologic composition further has a cryoprotectant. The cryoprotectant is a polyampholyte, preferably the polyampholyte is an ϵ-poly-L-lysine. The cryoprotectant is not DMSO or glycerol based. The cryoprotectant is suitable for direct implantation without washing from the allograft scaffold matrix in either a diluted or non-diluted state.